

10/540494

JCO Rec'd PCT/PTO 43 JUN 2005

Docket No.: 63628 (46342)
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Chieko Kitada et al.

Application No.: Not Yet Assigned

Confirmation No.: N/A

Filed: Concurrently Herewith

Art Unit: N/A

For: METASTIN DERIVATIVES AND USE
THEREOF

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new patent application submitted herewith.

A summary/abstract translation of the non-English language references is enclosed.

A copy of each reference on the PTO/SB/08 is attached.

BEST AVAILABLE COPY

A concise explanation of relevance of the items listed on form PTO/SB/08 is in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.


It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Please charge our Deposit Account No. 04-1105 in the amount of \$4,440.00 covering the fees set forth in 37 CFR 1.492(a), 1.492(c)(2), 1.492(b)(3), 1.492(h), 1.492(e), 1.492(d), and 1.492(f). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 63628 (46342). A duplicate copy of this paper is enclosed.

Dated: June 23, 2005

Respectfully submitted,

By


Gregory B. Butler, Ph.D.

Registration No.: 34,558

EDWARDS & ANGELL, LLP

P.O. Box 55874

Boston, Massachusetts 02205

(617) 439-4444

Attorneys/Agents For Applicant

BEST AVAILABLE COPY

Application No. (if known): 10/540,494


Attorney Docket No.: 63628 (46342)

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EV 654389320 US in an envelope addressed to:

MS PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on October 12, 2005
Date


Signature

Nicole McKinnon

Typed or printed name of person signing Certificate

Registration Number, if applicable

(617) 439-4444
Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Transmittal (1 page);
Information Disclosure Statement (2 pages);
Form PTO/SB-08 (with citations); and return receipt postcard.

10/540494

JCO8 PCT/PTO 23 JUN 2005

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	Not Yet Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Chieko Kitada
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	63628 (46342)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-6,800,611	10-05-2004	Nobutaka Fuji, et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
/CB/	BA	WO-00/24890	05-04-2000			✓
/CB/	BB	WO-01/44469-A1	06-21-2001			✓
/CB/	BC	WO-01/75104	10-11-2001			✓
/CB/	BD	WO-02/085399-A1	10-31-2002			✓
/CB/	BE	WO-02-092829-A1	11-21-2002			✓
/CB/	BF	WO-03/027149-A1	04-03-2003			✓
/CB/	BG	WO-03/060125-A1	07-24-2003			✓
/CB/	BH	WO-2004/080749-A2	09-23-2004			✓
/CB/	BI	WO-98/39448	09-11-1998			✓

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
/CB/	CA	Sang-Kyou Han, et al.; <i>Orphan G protein-coupled receptors MrgA1 and MrgC11 are distinctively activated by RF-amide-related peptides through the Gαq/11 pathway</i> "; PNAS; Vol. 99; No. 23; November 12, 2000; pps. 14740-14745		✓
ng	CB	Matthew D. Ringel, et al. " <i>Metastin receptor is overexpressed in Papillary Thyroid Cancer and Activates MAP Kinase in Thyroid Cancer Cells</i> "; The Journal of Clinical Endocrinology & Metabolism; 87(5); pps. 2399-2402		✓
/CB/	CC	Masato Kotsani, et al.; " <i>The Metastasis Suppressor Gene KiSS-1 Encodes Kisspeptins, the Natural Ligands of the Orphan G Protein-coupled Receptor GPR54</i> "; The Journal of Biological Chemistry; Vol 276; No. 37; September 14, 2001; pp. 34631-34636		✓
/CB/	CD	The gist of speech of the 53 th Pharmaceutical Society of Japan, 2003, Organic 2,m B-13-2, pp. 68.		✓

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Christina Bradley/ (07/23/2008)	Date Considered	
--------------------	----------------------------------	-----------------	--

496594

date missing